{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458275362
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = [[CD147]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 244096-20-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Gavilimomab''' (also known as '''ABX-CBL''') is a [[mouse]] [[monoclonal antibody]] intended for use as an immunosuppressive [[biologic medical product|biologic]] treatment of [[glucocorticoid]]-resistant [[graft versus host disease]]. It binds to the antigen [[CD147]].<ref name="findarticles" />  Gavilimomab proved slightly less effective than standard [[antithymocyte globulin]] therapy.<ref name="Macmillan-2007">{{Cite journal 
| author1 = Macmillan, ML
| author2 = Couriel, D
| author3 = Weisdorf, DJ
| author4 = Schwab, G
| author5 = Havrilla, N
| author6 = Fleming, TR
| author7 = Huang, S
| author8 = Roskos, L
| author9 = Slavin, S
| title = A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease
| journal = Blood
| volume = 109
| issue = 6
| pages = 2657â€“62
| date=Mar 2007
| doi = 10.1182/blood-2006-08-013995
| pmid = 17110457 | display-authors = 8
| last10 = Shadduck
| first10 = R. K.
| last11 = Dipersio
| first11 = J.
| last12 = Territo
| first12 = M.
| last13 = Pavletic
| first13 = S.
| last14 = Linker
| first14 = C.
| last15 = Heslop
| first15 = H. E.
| last16 = Joachim Deeg
| first16 = H.
| last17 = Blazar
| first17 = B. R.
}}</ref>

It was originally developed by [[Abgenix]],<ref name="findarticles">[http://findarticles.com/p/articles/mi_m0EIN/is_2001_Jan_10/ai_68950045/ findarticles.com: Sangstat to Provide Clinical Development Update At JP Morgan H&Q Conference in San Francisco]</ref> which was later acquired by [[Amgen]].

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies for tumors]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}